The role of intestinal flora on tumorigenesis, progression, and the efficacy of PD-1/PD-L1 antibodies in colorectal cancer.

Abstract

Intestinal flora affects the maturation of the host immune system, serves as a biomarker and efficacy predictor in the immunotherapy of several cancers, and has an important role in the development of colorectal cancer (CRC). Anti-PD-1/PD-L1 antibodies have shown satisfactory results in MSI-H/dMMR CRC but performed poorly in patients with MSS/pMMR CRC. In recent years an increasing number of studies have shown that intestinal flora has an important impact on anti-PD-1/PD-L1 antibody efficacy in CRC patients. Preclinical and clinical evidence have suggested that anti-PD-1/PD-L1 antibody efficacy can be improved by altering the composition of the intestinal flora in CRC. Herein, we summarize the studies related to the influence of intestinal flora on anti-PD-1/PD-L1 antibody efficacy in CRC and discuss the potential underlying mechanism(s). We have focused on the impact of the intestinal flora on the efficacy and safety of anti-PD-1/PD-L1 antibodies in CRC and how to better utilize the intestinal flora as an adjuvant to improve the efficacy of anti-PD-1/PD-L1 antibodies. In addition, we have provided a basis for the potential of the intestinal flora as a new treatment modality and indicator for determining patient prognosis.

• Authors: Sen Wang, Benling Xu, Yangyang Zhang, Guangyu Chen, Peng Zhao, Quanli Gao, Long Yuan
• Journal: Cancer biology & medicine (Cancer Biol Med) Vol. 21 Issue 1 (12 23 2023) ISSN: 2095-3941 [Print] China
• PMID: 38148328 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2024 Cancer Biology & Medicine.

Chemical References

• Programmed Cell Death 1 Receptor
• B7-H1 Antigen

Topics

• Humans
• Programmed Cell Death 1 Receptor
• B7-H1 Antigen
• Gastrointestinal Microbiome
• Colorectal Neoplasms (drug therapy)
• Carcinogenesis
• Cell Transformation, Neoplastic